Ampreloxetine

Generic Name: Ampreloxetine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈F_₃NO

CAS Number: 1227056-84-9

Unique Ingredient Identifier: 19997EZ42I

Background: Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Theravance Biopharma announced investor meetings at the 43rd Annual J.P. Morgan Healthcare Conference, Jan 13-16, 2025, in San Francisco. The company focuses on innovative medicines, including YUPELRI® for COPD and Ampreloxetine for MSA, aiming to enhance shareholder value.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy